In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Daiichi Sankyo to Strengthen Cardiovascular Field by Comarketing Diabetes Treatments, Focusing on SGLT-2 Inhibitor
August 8, 2012
-
REGULATORY MOF Wants Generic Drug Share to Reach European, US Levels: Budget Examiner Shinkawa
August 8, 2012
-
BUSINESS 6 Listed Wholesalers Post Low Price Settlement Rates as of End-June, Showing Declines Compared to 2 Years Earlier
August 7, 2012
-
BUSINESS Astellas to “Seek Every Opportunity” for Domestic Vaccine Business, Including Alliances with Foreign Companies
August 6, 2012
-
BUSINESS DSP to Establish Sales Force for Anticancer Drugs in North America
August 3, 2012
-
BUSINESS Daiichi Sankyo: April-June Nexium Sales 6% of Full-Year Target, Set to Boost Promotion after Lifting of Long-Term Prescription Ban
August 2, 2012
-
REGULATORY Council Approves Economic Revitalization Strategy with Priority on 3 Sectors Including Life Science
August 1, 2012
-
BUSINESS Sanofi-aventis Reaches Settlement with Sawai, Takata Seiyaku in Allegra Patent Dispute; Allegra’s Use Patent Validity Established
July 31, 2012
-
REGULATORY MHLW to Use Senshin-iryo System to Develop Anticancer Drugs from FY2013
July 30, 2012
-
BUSINESS DPP-4 Inhibitor “Indispensable” to Strengthen Priority Field: Kyowa Kirin
July 30, 2012
-
BUSINESS Chugai Had Tough Start in Final Year of Midterm Plan: Chairman Nagayama
July 30, 2012
-
BUSINESS Takeda Initiates PIII Trial for Anticancer Agent Motesanib in Asia
July 27, 2012
-
ORGANIZATION EFPIA Submits Opinion Letter to MHLW Calling for Review of Priority Focus on Japanese Companies for Blood Plasma Products
July 27, 2012
-
BUSINESS Taiho Licenses Anti-Allergy Drug from Faes Farma in Japan
July 26, 2012
-
REGULATORY MHLW Asks Sanofi Pasteur to Consider Reducing Price of IPV
July 25, 2012
-
ORGANIZATION Hiroshima Wholesale FTC Sees “Gradual Effects” in Correcting Labor Services in Cooperation with Pharmacists
July 25, 2012
-
BUSINESS Confident of Posting Sales of 100 Billion Yen with 3 Focal Products Including Teribone: Asahi Kasei Pharma President Asano
July 24, 2012
-
BUSINESS HBM Taking Advantage of Avian Biotechnology for Antibody Drug Discovery: President Toyoura
July 23, 2012
-
BUSINESS Inlyta as Standard Drug in Second-Line Treatment: Pfizer
July 20, 2012
-
REGULATORY Cost-Effective Assessments to Be Limited to Technologies for Which Alternatives Are Available: CSIMC
July 19, 2012
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…